atomoxetine (Strattera)

selective inhibitor of noradrenaline reuptake; RN refers to parent compound (-)-isomer; atomoxetine was originally called tomoxetine but changed to avoid any potential confusion with tamoxifen that might lead to errors in dispensing the drug

Also Known As:

Networked: 542 relevant articles (86 outcomes, 162 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Allen, Albert J: 34 articles (01/2015 - 01/2002)
2.	Kratochvil, Christopher J: 20 articles (04/2011 - 01/2002)
3.	Biederman, Joseph: 19 articles (01/2013 - 07/2002)
4.	Spencer, Thomas J: 19 articles (01/2011 - 07/2002)
5.	Michelson, David: 19 articles (11/2008 - 01/2002)
6.	Schacht, Alexander: 15 articles (07/2015 - 12/2007)
7.	Wehmeier, Peter M: 14 articles (07/2015 - 12/2007)
8.	Dittmann, Ralf W: 14 articles (07/2015 - 12/2007)
9.	Escobar, Rodrigo: 14 articles (01/2015 - 06/2009)
10.	Newcorn, Jeffrey H: 14 articles (01/2015 - 07/2002)

Related Diseases

1.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 09/01/2014 - "Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials." 07/01/2004 - "Mean reductions in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored total score were significantly greater for patients randomized to atomoxetine, beginning at the first visit after the initiation of treatment and continuing at all subsequent visits. " 01/01/2004 - "Mean reductions in the scores on the Clinician Global Impression of Severity Scale, patient-rated CAARS and Wender-Reimherr Adult Attention Deficit Disorder Scale were also significantly greater with atomoxetine than with placebo. " 01/01/2004 - "Mean reductions in the scores on the Clinician Global Impression of Severity Scale, patient-rated CAARS and Wender-Reimherr Adult Attention Deficit Disorder Scale were also significantly greater with atomoxetine than with placebo. " 11/01/2009 - "To test the hypothesis that first-line treatment with atomoxetine provides superior efficacy than placebo for up to 12 weeks in improving the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD). "
2.	Attention Deficit and Disruptive Behavior Disorders (Oppositional Defiant Disorder) 11/01/2009 - "The primary aim of this study was to assess the efficacy of atomoxetine in improving ADHD and ODD symptoms in paediatric patients with ADHD and comorbid oppositional defiant disorder (ODD), non-responders to previous psychological intervention with parent support. " 09/01/2009 - "Therapy with atomoxetine has been associated with statistically significant improvements in symptoms of oppositional defiant disorder in most, but not all, studies. " 11/01/2010 - "Moreover, atomoxetine was associated with significant improvements in ADHD and oppositional defiant disorder symptoms at home and school and enhanced functioning in both domains (Impairment Rating Scale: all P < .001). " 02/01/2008 - "It remains uncertain, however, whether atomoxetine exerts a specific and enduring effect on oppositional defiant disorder symptoms." 02/01/2008 - "Repeated-measures analysis demonstrated a statistically significant difference favoring atomoxetine over placebo in the reduction of Swanson, Nolan, and Pelham Rating Scale-Revised oppositional defiant disorder total scores. "
3.	Dyslexia (Alexia) 11/01/2013 - "The atomoxetine-treated dyslexia-only subjects significantly improved from baseline to week 32 on ADHDRS-IV-Parent:Inv Inattentive subscale, K-SCT Parent and Teacher subscales, and WMTB-C Phonological Loop and Central Executive component scores. " 11/01/2013 - "At week 16, atomoxetine treatment resulted in significant (p<0.05) improvement from baseline in subjects with ADHD+D versus placebo on ADHDRS-IV-Parent:Inv Total (primary outcome) and subscales, ADHDRS-IV-Teacher-Version Inattentive subscale, K-SCT Interview Parent and Teacher subscales, and WMTB-C Central Executive component scores; in subjects with Dyslexia-only, atomoxetine versus placebo significantly improved K-SCT Youth subscale scores from baseline. " 01/01/2009 - "Though limited by small sample size, group differences in relation to the comparable changes in improvement in ADHD symptoms could suggest that brain systems related to the therapeutic benefit of atomoxetine in reducing ADHD symptoms may be different in individuals with ADHD+D and ADHD without dyslexia. " 11/01/2013 - "Atomoxetine treatment improved ADHD symptoms in subjects with ADHD+D and ADHD-only, but not in subjects with dyslexia-only without ADHD. " 11/01/2013 - "Children and adolescents (10-16 years of age) with ADHD+D (n=124), dyslexia-only (n=58), or ADHD-only (n=27) received atomoxetine (1.0-1.4 mg/kg/day) or placebo (ADHD-only subjects received atomoxetine) in a 16 week, acute, randomized, double-blind trial with a 16 week, open-label extension phase (atomoxetine treatment only). "
4.	Substance-Related Disorders (Drug Abuse) 01/01/2004 - "Atomoxetine is a valuable new treatment option for adults with ADHD and is particularly useful in patients who are at risk for substance abuse or who do not wish to take a controlled substance." 01/01/2004 - "Atomoxetine is a valuable new treatment option for adults with ADHD and is particularly useful in patients who are at risk for substance abuse or who do not wish to take a controlled substance." 05/01/2009 - "If there is a risk of substance abuse, both atomoxetine and ER-MTF are the preferred treatment. " 11/01/2005 - "Alcohol dependence, but not drug dependence or drug abuse, was predictive of the selection of atomoxetine over a short-acting stimulant (OR 2.98, 95% CI 1.25-7.09). " 09/01/2007 - "After adjusting for patient characteristics including substance abuse, depression, and the Charlson Comorbidity Index, adults treated with OROS-MPH had, on average, slightly lower medical and total medical and drug costs than those treated with MAS-XR or atomoxetine over the 6-month period after drug therapy initiation. "
5.	Tourette Syndrome (Tourette's Syndrome) 09/01/2006 - "Is atomoxetine also effective in patients suffering from Tourette syndrome?" 11/01/2014 - "[Treatment of Tourette syndrome by tomoxetine hydrochloride in older children]." 01/01/2008 - "Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome." 08/01/2007 - "Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement." 01/01/2008 - "This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS). "

Related Drugs and Biologics

1.	Methylphenidate (Ritalin)
2.	Norepinephrine (Noradrenaline)
3.	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)
4.	Amphetamine (Amfetamine)
5.	Carbon Monoxide
6.	Guanfacine (Tenex)
7.	Cytochrome P-450 CYP2D6 (CYP2D6)
8.	lisdexamfetamine dimesylate
9.	SLI381
10.	Dextroamphetamine (Dexedrine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Stents
3.	Aftercare (After-Treatment)
4.	Individualized Medicine
5.	Drug-Eluting Stents